Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 24;18(3):e1010093.
doi: 10.1371/journal.ppat.1010093. eCollection 2022 Mar.

Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2

Oscar Rosas Mejia  1 , Erin S Gloag  1 , Jianying Li  2 , Marisa Ruane-Foster  1 , Tiffany A Claeys  1 , Daniela Farkas  3 , Shu-Hua Wang  4 , Laszlo Farkas  3 , Gang Xin  1   2 , Richard T Robinson  1
Affiliations

Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2

Oscar Rosas Mejia et al. PLoS Pathog. .

Abstract

Mycobacterium tuberculosis (Mtb) and SARS-CoV-2 (CoV2) are the leading causes of death due to infectious disease. Although Mtb and CoV2 both cause serious and sometimes fatal respiratory infections, the effect of Mtb infection and its associated immune response on secondary infection with CoV2 is unknown. To address this question we applied two mouse models of COVID19, using mice which were chronically infected with Mtb. In both model systems, Mtb-infected mice were resistant to the pathological consequences of secondary CoV2 infection, and CoV2 infection did not affect Mtb burdens. Single cell RNA sequencing of coinfected and monoinfected lungs demonstrated the resistance of Mtb-infected mice is associated with expansion of T and B cell subsets upon viral challenge. Collectively, these data demonstrate that Mtb infection conditions the lung environment in a manner that is not conducive to CoV2 survival.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Mtb-infected ACE2 mice are resistant to secondary infection with CoV2.
(A) Experimental overview of our ACE2:CoV2 model studies, wherein mice were infected via aerosol with Mtb (Day -30) and challenged 30 days later (Day 0) with CoV2. On post-challenge Day 4, Day 7 and Day 14, tissues were collected for microbiological and immunological assessments. Experimental groups included ACE2 mice which were not infected with Mtb prior to CoV2 challenge (MtbNEGCoV2POS), ACE2 mice which were infected with Mtb but challenged with sterile saline (MtbPOSCoV2NEG), ACE2 mice which were infected with Mtb prior to CoV2 challenge (MtbPOSCoV2POS), and B6 controls which were infected with Mtb (to determine what if any impact human ACE2 transgene expression alone has on Mtb burdens). (B) The percent weight change experienced by each group of ACE2 mice following CoV2 challenge, as normalized to the original weight of each mouse. (C) CoV2 PFU burdens and (D) CoV2 N protein levels in the lungs of MtbNEGCoV2POS and MtbNEGCoV2POS mice. (E-G) Mtb CFU burdens in the (E) lungs, (F) spleen and (G) liver of MtbPOSCoV2NEG and MtbPOSCoV2POS mice, as well as B6 controls throughout the experiment time course. In each graph the following legend applies: MtbNEGCoV2POS, black circles or bars; MtbPOSCoV2NEG, gray circles; MtbPOSCoV2POS, white circles or bars. (H) Representative micrographs of AFB stained lung sections, as collected from MtbPOSCoV2NEG and MtbPOSCoV2POS mice at the indicated times post-challenge. In each micrograph, the large scale bar is 20 μM and inset scale bar is 5 μm. This experiment was repeated twice, each with similar results (4 mice/group/timepoint). *, p ≤ 0.05 as determined by either Student’s t-test or ANOVA; n.s., not significant.
Fig 2
Fig 2. CoV2-elicted cytokine responses are muted in the presence of Mtb infection.
On the indicated days, lung tissue from MtbNEGCoV2POS, MtbPOSCoV2NEG, MtbPOSCoV2POS and uninfected (UI) ACE2 mice was used to measure (A-C) protein levels of (A) IFNγ, (B) IL6 and (C) IL1β, as well as (D-I) mRNA levels of (D) IFNγ, (E) TNFα, (F) IFIT2, (G) IFIT3, (H) CCL2 and (I) IL10. This experiment was repeated twice, each with similar results (4 mice/group/timepoint). *, p ≤ 0.05 as determined by either Student’s t-test or ANOVA; §, significant relative to UI protein levels.
Fig 3
Fig 3. CoV2 infection of the airways and associated pneumonia are attenuated in the presence of Mtb.
(A-B) Representative micrographs of H&E stained lung sections, sections from each experimental group, as collected on (A) Day 4 or (B) Day 7 post challenge. (C-D) Quantitative analysis of H&E stains demonstrating (C) the size of each individual TB granuloma relative to the total lung area, with each dot representing an individual TB granuloma on the indicated Days, as well as (D) the cumulative area taken up by all granulomas in an individual mouse lung, with each dot representing an individual mouse on the indicated Days. Bars represent the mean +/- SD. (E-F) Representative micrographs of CoV2 N protein IHC stained lung sections from each experimental group, as collected on (E) Day 4 or (F) Day 7 post challenge. In each micrograph the large scale bar represents 200 microns; insets are 50 microns.
Fig 4
Fig 4. Mtb-infected B6 mice are resistant to secondary infection with MACoV2.
(A) Experimental overview of our B6:MACoV2 model studies, wherein mice were infected via aerosol with Mtb (Day -30) and challenged 30 days later (Day 0) with MACoV2. On post-challenge Days 4, 7 and14 we collected lung tissue for microbiological and immunological assessments. Experimental groups included B6 mice which were not infected with Mtb prior to MACoV2 challenge (MtbNEGMACoV2POS), B6 mice which were infected with Mtb but challenged with sterile saline (MtbPOSMACoV2NEG), and B6 mice which were infected with Mtb prior to CoV2 challenge (MtbPOSMACoV2POS). (B) The percent weight change experienced by each group of B6 mice following MACoV2 challenge, as normalized to the original weight of each mouse. (C-D) Lung viral burdens in MtbNEGMACoV2POS and MtbPOSMACoV2POS mice, as measured by (C) MACoV2 PFU or (D) MACoV2 N protein concentration on the indicated days, as well as (E) lung Mtb CFU burdens at the same timepoints. (F, H) Lung protein levels of (F) IFNγ and (H) IL6, as well as (G, I-K) mRNA levels of (G) IFNγ, (I) IFIT3, (J) IFITM3 and (K) ACE2. This experiment was repeated twice, each with similar results (4 mice/group/timepoint). *, p ≤ 0.05 as determined by either Student’s t-test or ANOVA; §, significant relative to UI protein levels.
Fig 5
Fig 5. Lung T and B cell subsets expand upon challenge of MtbPOS mice with MACoV2.
As an unbiased means to define and compare the lung immune landscape, live CD45+ cells were purified from the lungs of four experimental groups (Uninfected, UI; MtbNEGMACoV2POS; MtbPOSMACoV2NEG; MtbPOSMACoV2POS) on post-challenge Day 7 and used for scRNA analysis. (A-C) t-SNE plots of the resulting data, either (A-B) pooled across groups or (C) segregated by group to show (A) the extent of overlay and (B-C) clustering of data into 12 immune lineages. (D) The distribution and expression patterns of lineage defining genes which we used to annotate each cluster, as pooled from all group data (individual group data are shown in S1 Fig). (E) The proportion of each immune lineage in the lungs of each experimental group. MØ, macrophage; DC, dendritic cell; NK, natural killer.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, et al.. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. J Clin Invest. 2021;131(12). Epub 2021/05/05. doi: 10.1172/JCI149125 ; PubMed Central PMCID: PMC8203446. - DOI - PMC - PubMed
    1. Tamuzi JL, Ayele BT, Shumba CS, Adetokunboh OO, Uwimana-Nicol J, Haile ZT, et al.. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infect Dis. 2020;20(1):744. Epub 2020/10/11. doi: 10.1186/s12879-020-05450-4 ; PubMed Central PMCID: PMC7545798. - DOI - PMC - PubMed
    1. Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis (Edinb). 2021;126:102020. Epub 2020/11/28. doi: 10.1016/j.tube.2020.102020 ; PubMed Central PMCID: PMC7669479. - DOI - PMC - PubMed
    1. Mendy J, Jarju S, Heslop R, Bojang AL, Kampmann B, Sutherland JS. Changes in Mycobacterium tuberculosis-Specific Immunity With Influenza co-infection at Time of TB Diagnosis. Front Immunol. 2018;9:3093. Epub 2019/01/22. doi: 10.3389/fimmu.2018.03093 ; PubMed Central PMCID: PMC6328457. - DOI - PMC - PubMed
    1. Cobelens F, Nagelkerke N, Fletcher H. The convergent epidemiology of tuberculosis and human cytomegalovirus infection. F1000Res. 2018;7:280. Epub 2018/05/24. doi: 10.12688/f1000research.14184.2 ; PubMed Central PMCID: PMC5934687. - DOI - PMC - PubMed

Publication types